

Referências bibliográficas

1. Brennan F, Cousins MJ, - *Pain Relief as a human right. Pain: Clinical Updates 2004; 12(5):1-4*
2. *Circular Normativa N.º9/DGCG de 14/06/2003. A Dor como 5º Sinal Vital – Registo Sistemático da Intensidade da dor. Direcção-Geral da Saúde, Lisboa, 2003*
3. Martins, Maria Madalena; Travanca, Maria da Graça – A caminho do cuidar em enfermagem. Um outro olhar à pessoa com dor. *Dor*, 2003, vol 11 (4), pp 23-28), citando Mac Lellan (1997)
4. Programa Nacional de Controlo da Dor. Direcção-Geral da Saúde, Lisboa, 2008.
5. Caron AT, Lynn J, Keaney P. *End of life care in medical textbooks. Ann. Intern Med 1999; 130:82-6.*
6. Joranson DE. *Are out-care reimbursement policies a barrier to acute and cancer pain management? J Pain Symptom Manage, 1994; 8:221-34*
7. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, Cohen R, Dow L *Cancer related pain: a pan-European survey of prevalence, treatment and patient attitudes. Ann. Oncol. 2009; 20(8): 1420-33.*
8. Larue F, Colleau SM, Brasseur L, Cleelands CS. Multicentre study of cancer pain and its treatment in France. *BMJ 1995; 310:1034-7,*
9. Von Roenn JH, Cleeland CS, Gonin R, et al. Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. *Ann Intern Med 1993;119:121-6*
10. Bernabei R, Gambassi G, Lapane k, et al. Management of pain in elderly patients with cancer. SAGE Study Group. Systematic assessment of geriatric drug use via epidemiology. *JAMA 1998;279:1877-82.*
11. MacDDonald N, Ayoub J, Farley J, et al. A Quebec survey of issues in cancer pain management. *J. Pain Symptom Manage 2002;23:39-47.*
12. Hsieh RK. Pain control in Taiwanese patients with cancer: a multicenter, patient oriented survey. *J Formos Med Assoc 2005; 04:913-9*
13. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. *Eur J Pain 2006; 10:287-333.*)
14. 18 jun. 2008 ... Circular Normativa. Assunto: Programa Nacional de Controlo da Dor Nº11/DSCS/DPCD.DATA:18/06/08. Para: Todos os Serviços do Serviço Nacional de saúde. [em Linha]. Disponível em <http://www.min-saude.pt/rdonlyres/6861126B-C57A-46-e1-B065/316C0CF8DACD/0/ControlodaDor.pdf> [cedido pela Clínica da Dor do IPOLFG]

15. Murillo Capitan E, Duque Amusco A, Viricuela Exburu JÁ: Tratamiento etiológico o causal del dolor oncológico. In: El control del sufrimiento evitable. Terapia analgésica. E: Jaime Sanz Ortiz. Ed. You6Us, S:A: Madrida. 2001. 33-50
16. Ritto C. *et al*, Manual de dor Crónica, Clínica de Dor do IPOFG, Ed. Anedo, Fundação Grunenthal, Portugal
17. Cuesta F. Ruiz in: R e v. Soc. esp. Dolor 6: 29-40, 1998. Principios básicos para el control del dolor total. W. Astudillo*, C. Mendinueta**, E. Astudillo*** y S. Gabilonondo**** [em linha]. Disponível em http://paliativossinfronteras.com/upload/publica/dolor/programas-nacionales/EI%20dolor%20total%201999_01_06.pdf (Cedido pela Clínica da Dor do IPOLFG)
18. Sebon N, Dufaux E., Maladie D'Alzheimer et SOPHROLOGIE CAYCEDIENNE®, Approche théorique et protocoles adaptés, Ed. association Sophro'C, ISBN 978-2-95444054, France, Paris, Jan 2013; Pag.9-12
19. Hanks GW, De Conno F, Cherny, Hanna NM, Kalso E, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93
20. W.Styron, *Face à Trevas*, Galimard, 1990, pp.93-94
21. International Association for Study of Pain, Merksey 1979.
22. González Barón M. Conceptos de medicina paliativa, Tratamiento de soporte en oncología. Papel del médico de familia en la medicina paliativa oncológica. In: Tratado de Medicina Paliativa. M González báron. Ed. Médica Panamericana, SA. Madrid, 1996. 1-12
23. Regan jM and Peng P. Neurophysiology câncer pain. Cancer control 2000; 7:111-119
24. Gândara del Casrillo A, González Barón M. Introducción al dolor oncológico. In: Dolor y Cáncer. Hacia una oncología sin dolor. Ed. Medica Panamericana S:A: Madrid 2003.1-5
25. Tres Sánchez A, Pérez-Caballero C. Síndromes Clínicos de dolor en pacientes com câncer. In: Tratamiento del dolor en Oncología. Ed.; Eduardo Diaz-Rubio. Ed: You&Us, S:A: Madrid 2003. 35-57
26. SEMERGEN DoC, Documentos Clínicos SEMERGEN, SEMERGEN DoC en Manejo del dolor en AP.[em Linha] Disponível em http://www.semergen.es/semergen/microsites/semergendoc/dolor/dolor_complet.pdf [cedido pela Clínica da Dor do IPOLFG]

27. McMillan SC, Tofthagen C, Morgan MA. Relationships among pain, sleep disturbances, and depressive symptoms in outpatients from a comprehensive cancer center. *Oncol Nurs Forum* 2008; 35: 603-6.
28. Yaksh TL & Luo DZ. Anatomy of the pain processing system. In SD Waldman editor. *Pain management*. Philadelphia:Saunders;2007;11-20.
29. Wall e Melzack, 1982, citado em: Almeida A, Leite-Almeida H. Como é que as emoções controlam a dor? *Ser saúde*, 2006, 1:64-78.
30. Cassinelo Espinosa J. El dolor, Definición, tipos patogénicos, formas de presentación y evaluación del dolor. In: *Manual SEOM de Cuidados Contínuos*. Sociedade Española de Oncología Médica. Edt.:Dispublic, S.L. 2004 (DL: M-41079-2004).445-72
31. Metzger, Christianne (et al) – *Cuidados de Enfermagem e dor*, Lusociência, loures, 2002
32. Scheffer, R. Dolor en la enfermedad terminal. In: *Terapêutica del dolor*, editando por K.M. Foley y R.M. Payne, Mexico, Interamericana.1992, 38-51
33. Saunders, C.M., Baines M., *Living with Dying. The management of the terminal disease*. Londres, Oxford. Oxford University Press. 1983; 12-13
34. H.K. Beecher in: *R e v. Soc. esp. Dolor* 6: 29-40, 1998. Princípios básicos para el control del dolor total.
35. W. Astudillo*, C. Mendinueta**, E. Astudillo*** y S. Gabilonondo****[em linha]. Disponível em http://paliativossinfronteras.com/upload/publica/dolor/programas-nacionales/El%20dolor%20total%201999_01_06.pdf (Cedido pela Clínica da Dor do IPOLFG)
36. Caseiro, José M – Editorial I – As vitórias da APED. *Dor*, 2003, vol 11 (2), p.3
37. Deodato, Sandra – Cuidar o doente com dor: breve reflexão. *Dor*, 2003, vol 11(4), p.29
38. Ritto A. Cristina – *A Dor e a Prática de Enfermagem. A dor como 5º sinal vital* (Tese de Mestrado em Oncologia
39. McFaferry, Margo;Pasero, Chris – *Pain: clinical manual* 2ª Ed. St Louis: Mosby. 1999, 398p
40. Azevedo, Luís Filipe, *et al* – Tradução, adaptação cultural e estudo multicêntrico de validação de instrumentos para rastreio e avaliação do impacto da dor crónica. *Dor*, 2007, vol 15(4)
41. Costa, M. Arminda – *Relação enfermeiro-doente*, In: Patrão Neves, M.C.; Pacheco, Susana – *Para uma Ética de Enfermagem – Desafios*. Coimbra: G.C. – Publicações, Lda., 2004, p 95-108

42. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, Cohen R, Dow L *Cancer related pain: a pan-European survey of prevalence, treatment and patient attitudes. Ann. Oncol.* 2009; 20(8): 1420-33
- 43 Ordem dos Enfermeiros – CONSELHO DE ENFERMAGEM – Dor – guia Orientador de Boa Prática, 2008, 55p
44. Portugal, MINISTÉRIO DA SAÚDE, Direcção Geral de Saúde – Orientações técnicas sobre a avaliação da dor nas crianças, Lisboa, 2010
45. Portugal, MINISTÉRIO DA SAÚDE, Direcção Geral de Saúde – Circular Normativa n.º 09 de 14/06/2003, Lisboa, 2003
46. Guarda, Hirondina – Escala Dolopus: Avaliação comportamental da pessoa idosa (Tese de Mestrado em Cuidados Paliativos). Lisboa, 2006
47. Dolopus 2 Brief [on line]. Agosto 2008 [acedido em 05.09.2011]. Disponível em http://prc.coh.org/PainNOA/Dol%20_B.pdf (Cedido pela Clínica da Dor do IPOLFG)
48. Avaliação da Dor na Demência Avançada (PAINAD) Breve [on line]. Junho de 2008 [acedido em 05.09.2011]. Disponível em: http://prc.coh.org/PainNOA/PAINAD_B.pdf (cedido pela Clínica da Dor do IPOLFG)
49. Julião, Miguel *et al* – CEMBE da FMUL – NOC da dor neuropática localizada. *Dor*, 2011, vol.19(3), p.10
50. Freynhagen, R *et al* – *Current Medical Research and Opinion*, 2006, vol.22(10), p.1911 n- 1920. PD-Q – Portugal/Portuguese – Final version, 25 Junho 2007 – Mapi Research Institute
51. Costa I, in *Manual de Dor Crónica Clínica de Dor do IPOFG*, Ed. Anedo, Fundação Grunenthal, Portugal, pp.65-66
52. Willis WD, Westlund KN, Neuroanatomy of pain system and the pathways that modulate pain. *J Clin Neurophysiol.* 1997; 13:2-31
53. Todd AJ, Anatomy of primary afferents and projection neurons in the rat spinal dorsal horn with particular emphasis on substance P and the neurokinin 1 receptor. *Exp Physiol* 2002; 87:245-249
54. Dostrovsky JO, Role of thalamus in pain. *Prog brain Research* 2000; 129:245-257
55. Melzack R & Casey KL Sensory, motivational, and central control determinants of pain. *The skin senses.* Springfield; 1968;423-443
56. Dickenson aH, Chapman V, Green GM, The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. *Gen Pharmacol* 1997; 28:633-638
57. Torrance N, Smith BH, Bennett MI,. Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin. *BMC Family Practice* 2007;24:481-5

58. Herr K,. Neurophatic Pain: A guide to Comprehensive Assessment. *Pain Manage Nursing* 2004;5(4):9-18
59. Gilron I, Watson PN, Moulin DE. Neurophatic Pain: a practical guide for the clinician, *Can Med Assoc J* 2006;175(3):265-75
60. Vadalouca A, Siafka J, Vrachnou E. Therapeuthic Management of Chrohnic Neurophatic Pain. *Ann NY Acad Sci* 2006;1088:164-86
61. Chong MS, Bajwa ZH,. Diagnosis and Treatment of Neurophatic Pain. *J Pain Symptom Manage* 2003;25:S4-S11
62. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neurophatic pain conditions: A descriptive study. 2002-2005. *BMC Family Practice* 2008;26(9):1-9
63. Bouhassira D, Lantéri-Minet M, Attawl N, Touboul C. Prevalence of chronic pain with neurophatic characteristics in the general population. *Pain* 2008;136:380-7
64. Merskey H, Bogduk N,. classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. 2 ed. Seattle: IASP Press; 1994:212
65. Treede RD, Jensen TS, Gruccu G, Dostrovsky JO, Griffin JW *et al.* Redefinition and a grading system for clinical and research purposes. *Neurology* 2008;70:160-5
66. Nicholson B. Differential diagnosis: nociceptive and neurophatic pain. *Am J Manag Care* 2006;12:S256-S262
67. Dworkin RH,. An overview of Neurophatic Pain: Syndromes, Symptoms, signs and Several Mechanisms. *Clin J Pain* 2003;18:343-9
- 68 Dworkin RH, Backonja M, Farrar JT, Finnerup NB, Jensen TS, *et al.* Pharmacology management of neurophatic pain: Evidence-based recommendations. *Pain* 2007;132-237
69. Arstein P. Chronic Neurophatic Pain: Issues in Patient Education. *Pain Management Nursing* 2004;5(4):31-41
70. Leo RJ, Latif T. Repetitive Transcranial Magnetic stimulation in Experimentally Induced in Chronic Neurophatic Pain: a Review. *J Pain* 2007;8(6):453-9
71. Closs SJ, Staples V, Bennett MI, Briggs M. Managing the Symptoms of Neurophatic Pain: na Exploration of Patients' Experiences. *J Pain Symptom Manage* 2007;34(4):422-33
72. Chen H, Lamer TJ, Rho RH, Marshall KA, Sitz man BT, Ghazi SM *et al.* Contemporary Management of Neurophatic Pain for Primary Care Physician. *Mayo Clin Proc* 2004;79(12):1533-45
73. Mercadante S. The use of rapid onset opioids for breskthrough cancer pain: The challange of its dosing. *Crit Ver Oncol Hematol* 2011;80(3):460-5

74. Hodger R. *Cancer patient's needs and concerns when using narcotic analgesics. Em: Hills Cs, Fields WS, editors. Drug treatment of cancer pain in a drug-oriented society. Advances in Pain Research and Therapy, Vol. 11. New York: Raven Press; 1989:91-9*
75. Anderson KO, Richman SP, Hurley J, Palos G, Valero V, Mendoza TR, Gning L, Cleeland CS. *Cancer pain management among and underseved minority outpatients: perceived needs and barriers to optimal control. Cancer 2002: 94:2295-304*
76. Cleeland CS, Cleeland LM, Dar R, Rinehart LC. *Factors influencing physicians management of cancer pain. Cancer 1986;58:796-800*
77. World Health Organization. *Cancer pain relief, 2nd edn. World Health Organization, Geneva, Switserland, 1990. Acedido em 11 de Abril de 2009 em www.whqlibdoc.who.int/publications/9241544821.pdf [cedido pela Clínica da Dor do IPOLG]*
78. Abril de 2009 em www.whqlibdoc.who.int/publications/9241544821.pdf [cedido pela Clínica da Dor do IPOLFG]
79. Anderson BJ. *Comparing the efficacy of NSAIDs and paracetamol in children. Pediatr Anasteth 2004;14:201-17*
80. Kumpufainen E, Kokki H, Heikkinen M, Savolainen J, Laisalmi M. *Paracetamol (Acetaminophen) Penetrates Really Into the Cerebrospinal Fluido for Children After Intravenous Administration. Pediatrics 2007;119(4);766-71*
81. Piletta P, Porchet HC, Dayer P. *Central analgesic effect of acetaminophen but not of aspirin. Clin Pharmacol Ther 1991;49:350-4*
82. Gwilt JR, Robertson A, Goldman L, Blanchard AW. *The absorbtion characteristics of parazcetamosl in man. J Pharm Pharmacol 1963;15:445*
83. Korpela R, Korvenoja P, Meteroja O. *Morphine-sparing effect of acetaminophen in pediatric day-case surgery. Anesthesiology 1999;91:442-7*
84. Granry JC, Rod B, Monrigal JP, *et al.* *The analgesic efficacy of an injectable prodrug of acetaminophen in children after orthopaedic surgery. Paediatr Anaesh 1997;7:449-9*
85. Muratl, Baujard C, Foussat C, *et al.* *Tolerance and analgesic efficacy of a new IV paracetamol solution in children after inguinal hernia repair. Pediatr Anaesh 2005;94:642-88*
86. Ang ET, Goldfarb G, Boccard E. *Analgesic efficacy of propacetamol hydrochlorate 2 g versus pentazocine 30 mg after orthopedic surgery. Eur J Pain 1990;11:137-42*
87. Moller PL, Sindet-Pedersen S, Petersen CT, *et al.* *Onset of acetaminophen analgesia: Comparison of oral and intravenous routes after third molar surgery. Br J Anaesh 2005;94:642-88*

88. Bozzo J, Escolar G, Hernandez MR, Galan AM, Ordinas A. Prohemorrhagic potencial of dipyrone, ibuprofen, ketorolac and aspirine: mechanisms associated with blood flow and erythrocyte deformability. *J Cardiovasc Pharmacol* 2001;38(2):138-90
89. Alves D, Duarte I. Involvement of ATP- Sensitive K⁺ Channels in the peripheral antinoceptive effect induced by dipyrone. *Eur J Pharmacol* 2002;441(1-2):47-52
90. Edwards JE, Meseguer F, Faura C, Moore RA, McQuay HJ. Single dose dipyrone for acute renal colic pain. *The Cochrane Database of Systematic Reviews* 2002, Issue 4
91. *Prontuário Terapêutico (9ª edição)*. Infarmed. Ministério da Saúde. Lisboa. 2012:138
92. Figueiroa M, Guercio M, Paiva A, Lares M, Hong A,. Efecto de la dipirone sobre la agregación plaquetaria. *Arch Venez Farmacol Ter* 2006;25(1):39-44
93. Souza FR, Souza VT, Ratzlaff V, Borges LP, Oliveira MR, Bonacorso HG *et al*. Hypothermic and antipyretic effects of 3-methyl- and 3-phenil-5-trichloromethyl-4,5-dihydro-1H-pyrazole-1-carboxyamides in mice. *Eur J Pharmacol* 2002; 451(2):141-7
94. Capuano A, de Corato A, Treglia M, Tringali G, Navarra P. Flupirtine antinoception in the rat orofacial formalin test: na analysis of combination therapies with morphine and tramadol. *Pharmacol Biochem Behav* 2011;97(3):544-50
95. Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. *Drugs* 1993;45(4):548-69
96. Abrams SML, Backer LRI, Crome P, White AST, Johnston A, Anker SI, Warrington SJ, Turner P, Niebch G. Pharmacokinetics in elderly volunteers and in patients with moderate renal impairment. *Postgrad Med J* 1988;64:361-3
97. Mamdani M, Rochon PA, Juurlink DN, *et al*. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. *BMJ* 2002; 325:1-6
98. Solomon D, Goodson N, Shrank W, Avorn J. NSAIDs and Cox-2 Inhibitors: What Now? A review of evidence for the practicing physician. Independent Drug Information Service. October 2005. Acedido em 12 de Abril de 2011 em http://www.rxfacts.org/pdf/NSAIDS_Cox2%20Inhibitors_ev%20doc_2009.02.27.pdf
- [Cedido pela Consulta da Dor do IPOFG]
99. Bennet JS, Daugherty A, Harrington D, Greenland P, Roberts H, Taubert KA,. The Use of nonsteroidal anti-inflammatory drugs (NSAIDs): A science advisory from the American Heart Association. *Circulation* 2005;111(13):1713-6
100. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, *et al*. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. *BMJ* 2011;342:c7086

101. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. *Ann Intern Med* 1991;115(10):787-96
102. Johnson Ag, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? *Ann Intern Med* 1994;121:289-300
103. Infarmed – Circular Informativa n.º072/CA. Lisboa. 2005. Acedido em <http://www.infarmed.pt/portal/pls/potal/docs/1/21361.pdf> em 17 Março de 2011 [cedido pela Consulta da Dor do IPOLFG]
104. Jaffe JH, Martin WR. Opioid analgesics and antagonists. Goodman GA, Goodman LS, Rall TW, Murad F, eds. *The Pharmacological basis of therapeutics*. 7 ed. New York. MacMillan Publishing Co, 1985:491-531
105. Madadi P, KorenG. Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. *Pharmacogenetics* 2008;9:1267-84
106. Sindrup SH, Brosen K, Bjerring P, Arendt-Nielsen L, Larsen U, Angelo HR, *et al*. Codeine increases pain thresholds to copper vapour laser stimuli extensive but not poor metabolizers of sparteine. *Clin Pharmacol Ther* 1990;48:688-93
107. Max MB, Laska EM. Single-dose analgesic comparisons. Em Max MB, Portenoy RK, Lawska EM.eds. *The design of analgesic clinical trials*. New York: Raven Press, 1991:55-95
108. Meadows BJ. Codeine combinations in clinical practice. *Current Therapeutic Research. Clinical and Experimental* 1984;35:501-10), (Beaver WT,. *Combination analgesics*. *Am J Med* 1984;9:38-53
109. *Prontuário Terapêutico (9ª edição)*. Infarmed. Ministério da Saúde. Lisboa. 2010:257
110. Dayer P, Desmeureles J, Collart L. Pharmacology of tramadol. *Drugs* 1997;53(Suppl2):18-23
111. Grond S, Sablotzki A. Clinical pharmacology of tramadol. *Clin Pharmacokinet* 2004;43(13):879-923
112. *Prontuário Terapêutico (9ª edição)*. Infarmed. Ministério da Saúde. Lisboa. 2010:556
113. Dworkin RH, O'Connor AB, Backoja M, Ferrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice ASC, Stacey BR, Treede RD, Turk DC, Wallace MS. Pharmacologic management of neuropathic pain; Evidence-based recommendations. *Pain* 2007;132(3):237.51
114. Hanks GW, De Conno F, Cherny, Hanna NM, Kalso E, *et al*. Morphine and alternative opioids in cancer pain: the EAPC recommendations. *Br J Cancer* 2001;84:587-93

115. Skaer TL. Transdermal opioids for cancer pain. *Health and Quality of Life Outcomes* 2006;4:24
116. Muijers RBR, Wagstaff AJ. Transdermal Fentanyl. An updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. *Drugs* 2001;61:2289-307
117. Pergolizzi J, Boger RH, Budd K, DAhan A, Erdine S, Hans G, Krees H-G, Langford R, Likar R, Raffa RB, Sacerdote P. Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone). *Pain Practice* 2008;8(4):287-313
118. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain. Preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. *J Pain Symptom Manage* 1997;13:254-61
119. Donner B, Zenz M, Strumpf M, RAber M,. Long-term treatment of cancer pain with transdermal fentanyl. *J Pain Symptom Manage* 1998;15:168-75
120. Payne R, Mathias SD, Pasta DJ, Wanke La, Williams R, et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. *J Clin Oncol* 1998;16:1588-93
121. Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, Villari P, Ficorella C, Gebbia V, et al. Sustained-release oral morphine versus transdermal fentanyl. *Eur J Pain* 2008;12(8):1040-6
122. Weschules DJ, Bain KT, Reifsnyder J, McMath JA, Kupperman DE, et al. Towards evidence-based prescribing at end of life : a comparative analysis of sustained release morphine oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction in hospice patients. *Pain Med* 2006;7:320-9
123. Kornick CA, Santiago-Palma J, Moryl N, Payne R, Obbens EA. Benefit-Risk Assessment of Transdermal Fentanyl for the Treatment of Chronic Pain. *Drug Safety* 2003;26:951-73
124. Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. *Curr Med Res Opin* 2004;20:1419-28)
125. Heit HA, Goulay DL. Buprenorphine new tricks with an old molecule for pain management. *Clin J Pain* 2008;24(2):93-7
126. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. *J Pain Symptom Manage* 2005;29:297-326
127. Evans HC, Easthope SE,. Transdermal buprenorphine. *Drugs* 2003;63:1990-2010

128. Boehme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. *Pain Clinic* 2003;15:193-202), 192(Sttil R, Transdermal buprenorphine in the treatment of chronic pain. *Expert Rev Neurother* 2005;5:315-23
129. Boehme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. *Pain Clinic* 2003;15:193-202
130. Omote K, Ohmori H, Kawamata M, Matsumoto M, Namiki A. Intrathecal buprenorphine in the treatment of phantom limb pain. *Anesth Analg* 1995;80:1030-2)
131. Benedetti F, Amanzio M, Casadio C, et al. Postoperative pain and superficial abdominal reflexes after posterolateral thoracotomy. *Ann Thorac surg* 1997;64:207-10
132. Kumar MG, Lin S. Hydromorphone in the management of cancer-related pain: an update on routes of administration and dosage forms. *J Pharm Pharmaceut Sci* 2007;10(4):504-18
133. Quigley C, Wiffen P. A systematic review of hydromorphone in acute and chronic pain. *J Pain Symptom Manage* 2003;25:169-78
134. Murray A, Hagen NA. Hydromorphone. *J Pain Symptom Manage* 2005 ;29(Suppl5):S57-S66
135. Amabile CM, Bowman BJ, Overview of oral modified-release opioid products for the management of chronic pain. *Ann Pharmacother* 2006;40:1327-35
136. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. *Curr Med Res Opin* 2006;22:1879-92
137. Moulin DE, Clark AJ, Speechley M, et al. Chronic pain in Canada: prevalence, treatment, impact and the role of opioid analgesia. *Pain Res Manag* 2002;7:179-84
138. Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT, Dornseif BE, Damask MC. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or non-malignant pain. *J Pain Symptom Manage* 2002;23:355-68
139. Hale M, Tudor IC, Khana S, et al. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label non inferiority analysis. *Clin Ther* 2007;29:874-88
140. Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. *J Pain Symptom Manage* 1995;10:184-86

141. Tzschentke Tm, Christoph T, Kögel B, et al. A novel μ -opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. *J Pharmacol Exp Ther* 2007;323(1):265-76
142. Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol hydrochloride :analgesic μ -opioid receptor agonist noradrenaline reuptake inhibitor. *Drugs Future* 2006;1(12):105-61
143. Kneip C, Terlinden R, Beier H, et al. Investigations into drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. *Drug Metab Letters* 2008;2:2:67-75
144. Hartrick CT, Rozek RJ. Tapentadol in Pain Management. A μ -Opioid Receptor Agonist and Noradrenaline Reuptake Inhibitor. *CNS Drugs* 2011;25(5):359-70
145. Portenoy RK. Opioid therapy for chronic nonmalignant pain: A review of the critical issues. *J Pain Symptom Manage* 1996;11:203-17
146. Porreca F, Ossipov MH. Nausea and Vomiting Side Effects with Opioid Analgesics during Treatment of Chronic Pain: Mechanisms, implications, and Management Options. *Pain Medicine* 2009;10(4):654-62
147. Harris J-D. Management of expected and unexpected opioid-related side effects. *Clin J Pain* 2008;24:S8-13
148. Forman WB. Opioid analgesic drugs in the elderly. *Clin Geriatr Med* 1996;12:489-500
149. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. *J. Clin Oncol* 2001;19:2542-24
150. Mercadante S. Opioid rotation for cancer pain: rational and clinical aspects. *Cancer* 1999;86:1865-66
151. Moore RA, McAduy HJ,. Prevalence of opioid adverse events in chronic non-malignant pain: Systematic review and randomized trials of oral opioids. *Arthritis Res Ther* 2005;7:R1046-51
152. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: A Systematic review. *J Pain Symptom Manage* 2003;26:1026-48
153. Villars P, Dodd M, West C, et al. Differences in the prevalence of severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. *J Pain Symptom Manage* 2007;33:67-77
154. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom RL. Side effects of opioids during short-term administration: effect of age, gender, and race. *Clin Pharmacol Ther* 2003;74:102-12

155. Portenoy RK, Farrar JT, Backonja MM, et al. Long-term use of controlled-release oxycodone for noncancer pain: Results of a 3-year registry study. *Clin J Pain* 2007;23:287-99
156. Herndon CM, Jackson KC II, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. *Pharmacotherapy* 2002;22:240-50
157. Rousseau P. Nonpain symptom management in terminal care. *Clin Geriatr Med* 1996;12:13-27
158. Swegle JM, Logemann C. Management of Common Opioid-induced Adverse Effects. *Am Fam Physician* 2006;74(8):1347-54
159. Kurz A, Sessler DI,. Opioid-induced bowel dysfunction: Pathophysiology and potential new therapies. *Drugs* 2003;63:649-71
160. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. *Am J Surg* 2001;183(5A suppl):11S-8S
161. Canty SL. Constipation as a side effect of opioids. *Oncol Nurs Forum* 1994;21:739-45
162. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. *J Pain* 2003;4:231-56
163. Cherny NI. The management of cancer pain. *CA Cancer J Clin* 2000;50:70-116
164. Jackson KC, Lipman AG. Drug therapy for delirium in terminally ill patients. *Cochrane DataBase Syst Ver* 2004;(2):CD004770
165. Swegle JM, Logemann C. Management of Common Opioid-induced Adverse Effects. *Am Fam Physician* 2006;74(8):1347-54
166. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. *J Pain* 2003;4:231-56
167. Dahan A. *New insights Into Buprenorphine's Respiratory Effects*. Stuttgart: Thieme-Verlag; 2005), 259
168. Dahan A, Teppema LJ. Influence of anaesthesia and analgesia on the control of breathing. *Br J Anaesth* 2003;91:40-9
169. Ward D, Dahan A. *Respiratory Pharmacology*, 7 ed. London: Arnold; 2004)
170. Watanabe S, Bruera E,. Corticosteroids as adjuvant analgesics. *J Pain Symptom Manage* 1991;9(7):442-5
171. Loblaw DA, Laperriere NJ,. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. *J Clin Oncol* 1998;16(4):1631-24

172. Feuer DJ, Broadly KE. Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. *Ann Oncol* 1999;10(9):1035-41
173. Vyvey M. Steroids as pain relief adjuvants. *Can Fam Physic* 2010;56:1295-7)
174. Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, *et al.* Drugs in palliative care: results from a representative survey in Germany. *Palliat Med* 2004;18(2):100-7
175. Lundström SH, Furst CJ. The use of corticosteroids in Swedish palliative care. *Acta Oncol* 2006;45(4):430-7
176. Gannon C, McNamara P. A retrospective observation of corticosteroid use at the end of life in a hospice. *J Pain Symptom Manage* 2002;24(3):328-34
177. Hardy JR, Rees E, Ling J, Burman R, Broadley K, *et al.* A prospective survey of the use of dexamethasone on a palliative care unit. *Palliat Med* 2001;15(1):3-8
178. Oliveira Jr JO. Dor Oncológica. *Acta Oncol Bras* 1994;14(1):11-25
179. Walsh TD, Caraceni AT, Fainsinger R, Foley KM, Glare P, Goh C, *et al.* Palliative medicine. New York, NY: Saunders; 2009
180. Sturdza A, Millar BA, Bana N, Laperriere N, Pond G, Wong RK, *et al.* The use and toxicity of steroids in the management of patients with brain metastases. *Support Care Cancer* 2008;16(9):1041-8
181. Krach EL. Pharmacotherapy of spasticity oral mediations and intrathecal Baclofen. *J Child Neurol* 2001;16(1):31-6)
182. Kita M, Goodkin DE. Drugs used to treat spasticity. *Drugs* 2000;59(3):487-95
183. Gatscher S, Becker R, Uhle E, Bertalanffy H. Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentation pain. *Acta Neurochir Suppl* 2002;9:75-6
184. Harmer JP, Larson BS,. Pain relief from baclofen analgesia in a neuropathic pain patient who failed opioid and pharmacotherapy: case report. *J Pain Palliat Care Pharmacother* 2002;16(3):61-4
185. Sharma R, Mathur R, Nayar U. GABA B mediated analgesia in tonic pain in monkeys. *Indian J Physiol Pharmacol* 1993;37(3):189-93
186. Zuniga RE, Pereira S, Abram SE. Intrathecal baclofen: a useful agent in the treatment of well-established complex regional pain syndrome. *Reg Anesth Pain Med* 2002;27(1):90-3
187. Sadiq SA, Poopatana CA. Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity. *J Neurol* 2007;254(10):1464-5

188. Taira T, Kawamura H, Tanikawa T, Iseki H, Kawabatake H, Takakura K. A new approach to control central deafferentation pain: spinal intrathecal baclofen. *Sterotact Funct Neurosurg* 1995;65(1-4):101-5
189. Gianino JM, York MM, Paice JÁ, Shot S. Quality of life: effect of a reduced spasticity from intrathecal Baclofen. *J Neuros Nurs* 1998;30:47-54
190. *Prontuário Terapêutico (9ª edição)*. Infarmed. Ministério da Saúde. Lisboa.2010:75
191. Browning R, Jackson JL, O'Malley PG. Cyclobenzaprime and Back Pain: a Meta-analysis. *Arch Intern Med* 2001;161:1613-20
192. Berry H, Hutchinson DR. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. *J Int Med Res* 1988;16(2):75-82
193. Pareek A, Chandurkar N, Chandanwale AS, Ambade R, Gupta A, Bartakke G. Aceclofenac-tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randozimized, multicentric, comparative study against aceclofenac alone. *Eur Spine J* 2009;18(12):1836-42
194. Savard J, Morin CM. Insomnia in the Context of Câncer: a Review of Neglected Problem. *J Clin Oncol* 2001;19(3):895-908
195. Davies A, Vriens J, Kennett A, McTaggart. Na observational study of oncology patients' utilization of breakthrough pain medication. *J Pain Symptom Manage* 2008;35:406-11
196. Bennett D, Burton AW, Fishman S, *et al*. Consensus panel recomenations for the assessment and management breakthrough pain.Part 2. Management. *Phar Ther* 2005;30:354-61
197. Davies AD, Dickman A, Reid C, Stevens A, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the science committee of the Association for Palliative Medicine of Great Britain and Ireland. *Eur J Pain* 2009;13:331-8
198. Mercadante S, Intravaia G, Vilari P, Ferrera P, Riina S, Mangione S. Intravenous morphine for episodic-breakthrough pain in na acute palliative care unit: a confirmatory study. *J Pain Symptom Manage* 2008;35:307-13
199. Bredenberg S, Duberg M, Lennernas B, *et al*. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. *Eur J Pharm Sci* 2003;20:327-34
200. Rauck RL, Tark M, Reyes E, *et al*. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. *Curr Med Res Opin*. 2009;25:2877-85

201. Verna P, Thakur AS, Deshmurk K, Jha AK, Verna S. Routes of drugs administration IJPSR Vol I Issui 2010, 54-59
202. International Journal of Pharmaceutical Studies and research. E.ISSN 2229-4619 PHAR 7633 Chapter 7. Routes of Administration
203. Rull M, Sardá I, Font M. Bloqueos centrales. En: Torres LM, editor. Medicina deo dolor. Barcelona. Masson; 1997:509-22
204. Lynn AM, Nespea MK, Bratton SL, Shen DD. Intravenous morphine in postoperative infants: intermitente bolús dosing versus targeted continuous infusions. Pain 2000 ; 88 :89-95
205. Torres LM, Collado F, Almarcha JM, Hertas VG. Tratamiento del dolor postoperatório com sistema PCA intravenoso. Comparación entre morfina, metamizol y buprenorfina. RevEsp Anestesiología y reanimación 1993; 40:18-4
206. Mayers S, Ferrero M. Fentanyl HLC patient-controlled iontophoretic Transdermal system for management of acute postoperative pain. Ann Pharmacoter 2006; 40:2178-86
207. Kapural L, Goldner J,. Interventional pain management. When / what therapies are best for low back pain. Current Opinion in Anaesthesiology;2005; vol.18:569-575
208. Rafael MD. Interventional Treatment of Cancer pain: the fourth Step in World Health Organization Analgesic Ladder?. Cancer Control. 2000, vol17.2:149-156
209. Staats P. Neuroaxial infusion for pain control: When, why to after the implant. Oncology.1999;13:58.52
210. Staats PS,. The pain-mortality link: unraveling the mysteries. In Payne R, Patt RB, Hill CS. Eds. Progress in Pain Research and Management. Vol.12. Seattle, WA: IASP Press;1998:145-156
211. Patt RB. Cancer Pain. Philadelphia, Pa: Lippincott Co:1993
212. Meckail NA, Malk O. Lumbar Sympathetic blockade. Technics in Reg Anesth Pain Manag. 2005;5:99-10136)
213. Eisenberg E, Carr DB, Chalmers TC. Neurilytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg 1995;80:290-295
214. Cohen SP, Dragovich A. Intrathecal analgesia. Med Clin North AM. 2007;91:251-70
215. Burton AW, Mendel E. Vertebroplasty and kyphoplasty. Pain Physician 2003;6:335-43)
216. Burton AW, Reddy SK, Shah HN, Tremont-Lukas I, Mendel E. Percutaneous vertebroplasty, a technic to treat refractory spinal pain in the setting of advanced metastatic cancer: a case series. J Pain Symptom Manage 2005;30:87-95
217. Pimentel FL, Qualidade de Vida e Oncologia, Almedina, 2006,pp.20-25

218. Breivik , Ventafridda V, Cohen R, Gallacher D, *Survey of chronic pain in Europe: Prevalence impact on daily life, and treatment.* Eur J Pain 2006; 10:287-333
218. Costa C, Magalhães H, Félix R, Costa A, Cordeiro S., O CANCRO E A QUALIDADE DE VIDA: A quimioterapia e outros fármacos no combate ao cancro. Lisboa Novartis, ISBN:972-9119-94-5, Pag.920-926
220. Marchand, C, Master Especialista em Sofrologia Caycediana; Revue Officielle de la Fondation Alfonso Caycedo, nº72, pp10-15
221. Guirao M.; PhD, La Neuropsychologie de la Sophrologie, Média-Sys-Tique Inc. Éditeurs ; Quebec ; Canadá
222. H.K. Beecher in: R e v. Soc. esp. Dolor 6: 29-40, 1998. Princípios básicos para el control del dolor total. W. Astudillo*, C. Mendiñeta**, E. Astudillo*** y S. Gabilondo**** [em linha). Disponível em http://paliativossinfronteras.com/upload/publica/dolor/programas-nacionales/EI%20dolor%20total%201999_01_06.pdf (Cedido pela Clínica da Dor do IPOLFG)
223. Abrezol R., Saber Tudo sobre a Sofrologia, Ed. Técnicas e Científicas Lda., Mafra; 2003; pp-19-90
224. Braverman, Un cerveau à 100%, ed. Th Souccard
225. Abrezol R., Cerveau & Conscience, de la matière et de l'esprit ; Ed. Bernet-Danilo ; 1999 ; Meschers : Cap III ; pp 142-163
226. Doiges N. Les étonnants pouvoirs de transformation du cerveau, ed. Pocket
227. David LEBRETON sociólogo e antropólogo, Professor na Universidade de Paris X
228. L Garcia Larrea Laboratoire de Neurophysiologie humaine. CERMEP